A drug or agent which antagonizes or impairs any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
| Member | Definition | Class |
|---|
| (E)-2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside | A stilbenoid that is trans-stilbene which has been substituted by hydroxy groups at positions 2, 3, 5, and 4', and in which the hydroxy group at positon 2 has then been converted to the corresponding the beta-D-glucoside. | (E)-2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside |
| 1,2-benzisothiazoline-3-one | An organic heterobicyclic compound based on a fused 1,2-thiazole and benzene bicyclic ring skeleton, with the S atom positioned adjacent to one of the positions of ring fusion. | benzo[d]isothiazol-3-one |
| 2-hydroxyacetanilide | A member of the class of phenols that is 2-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group. A positional isomer of paracetamol which possesses anti-inflammatory, anti-arthritic and anti-platelet aggregation properties. | 2-acetamidophenol; 2'-Hydroxyacetanilide |
| 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole | A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation. | [5-[1-(phenylmethyl)-3-indazolyl]-2-furanyl]methanol; lificiguat |
| 4-phenyl-3-furoxancarbonitrile | A 1,2,5-oxadiazole substituted by an oxido, cyano and phenyl groups at positions 2, 3 and 4, respectively. It is a vasodilator and inhibitor of platelet aggregation. | 4-phenyl-3-furoxancarbonitrile |
| 6-ketoprostaglandin e1 | A prostaglandin E that is prostaglandin E1 bearing a keto substituent at the 6-position. | 6-oxoprostaglandin E1 |
| 8-prenylnaringenin | A trihydroxyflavanone that is (S)-naringenin having a prenyl group at position 8. | sophoraflavanone B |
| acadesine | A 1-ribosylimidazolecarboxamide in which the carboxamide group is situated at position 4 of the imidazole ring, which is further substituted at position 5 by an amino group. A purine nucleoside analogue and activator of AMP-activated protein kinase, it is is used for the treatment of acute lymphoblastic leukemia and is reported to have cardioprotective effects. | acadesine |
| actinodaphine | An organic heteropentacyclic compound 6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]quinoline bering additional hydroxy and methoxy substituents at positions 10 and 11 respectively. | actinodaphnine |
| aglafoline | A heterotricyclic compound based on a 2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan framework substituted by hydroxy groups at positions C-1 and C-8b, a methoxycarbonyl group at C-2, a phenyl group at C-3, a 4-methoxyphenyl group at C-3a and methoxy groups at C-6 and C-8. A platelet aggregation inhibitor found in Aglaia elliptifolia and Aglaia odorata. | aglafolin |
| alprostadil | | prostaglandin E1 |
| aspirin | A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity. | acetylsalicylic acid |
| azelastine | A phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position. | azelastine |
| azelastine hydrochloride | The hydrochloride salt of azelastine. | azelastine hydrochloride |
| bay 11-7082 | A nitrile that is acrylonitrile in which the hydrogen located beta,trans to the cyano group is replaced by a tosyl group. It is an inhibitor of cytokine-induced IkappaB-alpha phosphorylation in cells. | (E)-3-tosylacrylonitrile |
| beraprost | An organic heterotricyclic compound that is (3aS,8bS)-2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan in which the hydrogens at positions 1R, 2R and 5 are replaced by (3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl, hydroxy and 3-carboxypropyl groups, respectively. It is a prostaglandin receptor agonist which is approved to treat pulmonary arterial hypertension in Asia. | beraprost |
| beraprost sodium | The organic sodium salt of beraprost. It is used in the treatment of chronic arterial occlusive disease and primary pulmonary hypertension in Japan. | beraprost sodium |
| bl 4162a | A 1,5-dihydroimidazo[2,1-]quinazoline having an oxo substituent at the 2-position and chloro substituents at the 6- and 7-positions. | anagrelide |
| cangrelor | A nucleoside triphosphate analogue that is 5'-O-[({[dichloro(phosphono)methyl](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]adenosine carrying additional 2-(methylsulfanyl)ethyl and (3,3,3-trifluoropropyl)sulfanyl substituents at positions N6 and C2 respectively. Used (in the form of its tetrasodium salt) as an intravenous antiplatelet drug that prevents formation of harmful blood clots in the coronary arteries. | cangrelor |
| carmoxirole | An indolecarboxylic acid that is indole-5-carboxylic acid bearing an additional 4-(4-phenyl-1,2,3,6-tetrahydropyridin-1-yl)butyl substituent at position 3. Selective, peripherally acting dopamine D2 receptor agonist. Modulates noradrenalin release and sympathetic activation. Displays antihypertensive properties in vivo. | carmoxirole |
| cilostazol | A lactam that is 3,4-dihydroquinolin-2(1H)-one in which the hydrogen at position 6 is substituted by a 4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy group. | cilostazol |
| clonixin | A pyridinemonocarboxylic acid that is nicotinic acid substituted at position 2 by a (2-methyl-3-chlorophenyl)amino group. Used (as its lysine salt) for treatment of renal colic, muscular pain and moderately severe migraine attacks. | clonixin |
| clopidogrel | A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group, the methylene hydrogen of which is replaced by a methoxycarbonyl group (the S enantiomer). A P2Y12 receptor antagonist, it is used to inhibit blood clots and prevent heart attacks. | clopidogrel |
| colforsin | A labdane diterpenoid isolated from the Indian Coleus plant. | forskolin |
| cytochalasin b | An organic heterotricyclic compound, that is a mycotoxin which is cell permeable an an inhibitor of cytoplasmic division by blocking the formation of contractile microfilaments. | cytochalasin B |
| diallyl trisulfide | An organic trisulfide that is trisulfane in which both of the hydrogens are replaced by allyl groups. A component of the essential oil of garlic and a major component of the traditional Chinese medicine allitridium, it exhibits antifungal, antitumour and antioxidant activity | diallyl trisulfide |
| dilazep | A member of the class of diazepanes that is 1,4-diazepane substituted by 3-[(3,4,5-trimethoxybenzoyl)oxy]propyl groups at positions 1 and 4. It is a potent adenosine uptake inhibitor that exhibits antiplatelet, antianginal and vasodilator properties. | dilazep |
| dipyridamole | A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots. | dipyridamole |
| droxicam | An organic heterotricyclic compound that is 2H,5H-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-dioxide substituted at positions 3 and 5 by pyridin-2-yl and methyl groups respectively. A prodrug of piroxicam, it is used for the relief of pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis. | droxicam |
| edoxaban | A monocarboxylic acid amide that is used (as its tosylate monohydrate) for the treatment of deep vein thrombosis and pulmonary embolism. | edoxaban |
| eptifibatide | A synthetic homodetic cyclic peptide comprising N(alpha)-(3-sulfanylpropanoyl)homoarginyl, glycyl, aspartyl, tryptophyl, prolyl and cysteinamide residues connected in sequence and cyclised via a disulfide bond. Derived from a protein found in the venom of the southeastern pygmy rattlesnake, Sistrurus miliarus barbouri, eptifibatide is an anti-coagulant that inhibits platelet aggregation by selectively blocking the platelet glycoprotein IIb/IIIa receptor, so preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands. It is used in the management of unstable angina and in patients undergoing coronary angioplasty and stenting procedures. | eptifibatide |
| fenofibrate | A benzochromenone that is 2,3-dihydro-1H-benzo[f]chromene substituted by an oxo group at position 3. It has been found to exhibit potential inhibitory activity against Sir2 proteins. | splitomicin |
| galgravin | A member of the class of aryltetrahydrofurans carrying two 3,4-dimethoxyphenyl substituents at positions 2 and 5 as well as two methyl groups at positions 3 and 4. | galgravin |
| glaucine | An aporphine alkaloid that is (S)-1,2,9,10-tetrahydroxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline in which the four phenolic hydrogens have been replaced by methyl groups. | (S)-glaucine |
| iloprost | A carbobicyclic compound that is prostaglandin I2 in which the endocyclic oxygen is replaced by a methylene group and in which the (1E,3S)-3-hydroxyoct-1-en-1-yl side chain is replaced by a (3R)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl group. A synthetic analogue of prostacyclin, it is used as the trometamol salt (generally by intravenous infusion) for the treatment of peripheral vascular disease and pulmonary hypertension. | iloprost |
| isobavachalcone | A member of the class of chalcones that is trans-chalcone substituted by hydroxy groups at positions 4, 2' and 4' and a prenyl group at position 3'. | isobavachalcone |
| lfm a13 | An enamide obtained by formal condensation of the carboxy group of (2Z)-2-cyano-3-hydroxybut-2-enoic acid with the amino group of 2,5-dibromoaniline. It is a dual-function inhibitor of Bruton's tyrosine kinase (BTK) and Polo-like kinases (PLK) that exhibits anticancer properties. | LFM-A13 |
| lysine clonixinate | An organoammonium salt obtained by combining clonixin with one molar equivalent of L-lysine. Used for treatment of renal colic, muscular pain and moderately severe migraine attacks. | clonixin lysine salt |
| methyl brevifolincarboxylate | An organic heterotricyclic compound that is 1,2,3,5-tetrahydrocyclopenta[c]isochromene substituted by hydroxy groups at positions 7, 8 and 9, oxo groups at positions 3 and 5 and a methoxycarbonyl group at position 1. Isolated from Phyllanthus urinaria and Phyllanthus niruri, it exhibits vasorelaxant activity. | methyl brevifolincarboxylate |
| milrinone | A member of the class of bipyridines that is 2-pyridone which is substituted at positions 3, 5, and 6 by cyano, pyrid-4-yl, and methyl groups, respectively. It is used (particularly intravenously, as the lactate) for the short-term management of severe heart failure. | milrinone |
| miroprofen | A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-(imidazo[1,2-a]pyridin-2-yl)phenyl group. A non-steroidal anti-inflammatory drug that also exhibits analgesic, antipyretic and platelet aggregation inhibition properties. | miroprofen |
| ML355 | A sulfonamide resulting from the formal condensation of the amino group of 2-aminobenzothiazole with the sulfo group of 4-[(2-hydroxy-3-methoxybenzyl)amino]benzenesulfonic acid. It is an inhibitor of 12-lipoxygenase, being developed by Veralox Therapeutics for the treatment of heparin-induced thrombocytopenia and thrombosis. | ML355 |
| mre 269 | A member of the class of pyrazines that is {4-[(propan-2-yl)(pyrazin-2-yl)amino]butoxy}acetic acid carrying two additional phenyl substituents at positions 5 and 6 on the pyrazine ring. The active metabolite of selexipag, an orphan drug used for the treatment of pulmonary arterial hypertension. | ACT-333679 |
| n-cinnamoyltyramine | A member of the class of cinnamamides that is tyramine substituted by a (1E)-3-oxo-1-phenylprop-1-en-3-yl group at the nitrogen atom. It is found in rice and exhibits an allelopathic effect to suppress the growth of weeds. | N-trans-cinnamoyltyramine |
| neobavaisoflavone | A member of the class of 7-hydroxyisoflavones that is 7-hydroxyisoflavone with an additonal hydroxy group at position 4' and a prenyl group at position 3'. Isolated from seeds of Psoralea corylifolia, it exhibits inhibitory activity against DNA polymerase and platelet aggregation. | neobavaisoflavone |
| plavix | | clopidogrel sulfate |
| procainamide | A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias. | procainamide |
| s-nitrosocysteine | An L-cysteine derivative in which the sulfur atom carries a nitroso substituent. A cell-permeable low-molecular-weight nitrosothiol and nitric oxide donor. | S-nitroso-L-cysteine |
| s-nitrosoglutathione | A glutathione derivative that is glutathione in which the hydrogen attached to the sulfur has been replaced by a nitroso group. | S-nitrosoglutathione |
| sciadopitysin | A biflavonoid that is a 7, 4', 4'''-trimethyl ether derivative of amentoflavone. | sciadopitysin |
| selexipag | A member of the class of pyrazines that is N-(methanesulfonyl)-2-{4-[(propan-2-yl)(pyrazin-2-yl)amino]butoxy}acetamide carrying two additional phenyl substituents at positions 5 and 6 on the pyrazine ring. An orphan drug used for the treatment of pulmonary arterial hypertension. It is a prodrug for ACT-333679 (the free carboxylic acid). | selexipag |
| sevoflurane | An ether compound having fluoromethyl and 1,1,1,3,3,3-hexafluoroisopropyl as the two alkyl groups. | sevoflurane |
| surfactin c | A cyclodepsipeptide that is N-[(3R)-3-hydroxy-13-methyltetradecanoyl]-L-alpha-glutamyl-L-leucyl-D-leucyl-L-valyl-L-alpha-aspartyl-D-leucyl-L-leucine in which the C-terminal carboxy group has been lactonised by condensation with the alcoholic hydroxy group. | surfactin C |
| syringetin | A dimethoxyflavone that is myricetin in which the hydroxy groups at positions 3' and 5' have been replaced by methoxy groups. | syringetin |
| taiwanin c | A furonaphthodioxole that is furo[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(8H)-one substituted by a 1,3-benzodioxol-5-yl group at position 5. It is a naturally occurring lignan extracted from Taiwania cryptomerioides and found to be a potential inhibitor of COX2 expression. | taiwanin C |
| tetramethylpyrazine | A member of the class of pyrazines that is pyrazine in which all four hydrogens have been replaced by methyl groups. An alkaloid extracted from Chuanxiong (Ligusticum wallichii). | tetramethylpyrazine |
| ticagrelor | A triazolopyrimidine that is an adenosine isostere; the cyclopentane ring is similar to ribose and the nitrogen-rich [1,2,3]triazolo[4,5-d]pyrimidine moiety resembles the nucleobase adenine. A platelet aggregation inhibitor which is used for prevention of thromboembolic events in patients with acute coronary syndrome. | ticagrelor |
| ticlopidine | A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group. | ticlopidine |
| troglitazone | | troglitazone |
| u 62840 | | treprostinil |
| vitexin | An apigenin flavone glycoside, which is found in the passion flower, bamboo leaves and pearl millet | vitexin |
| vorapaxar | A carbamate ester that is the ethyl ester of [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethynyl}-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl]carbamic acid. A protease-activated receptor-1 antagonist used (as its sulfate salt) for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease. It has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke and urgent coronary revascularisation. | vorapaxar |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 31.2757 | 1 | 11 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 15.8489 | 1 | 1 |
| 67.9K protein | Vaccinia virus | Potency | 14.3657 | 2 | 5 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 26.9965 | 3 | 12 |
| acid sphingomyelinase | Homo sapiens (human) | Potency | 25.1189 | 1 | 1 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 25.9337 | 2 | 6 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 21.6478 | 2 | 22 |
| alpha-galactosidase | Homo sapiens (human) | Potency | 41.6060 | 2 | 3 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 20.5049 | 1 | 5 |
| Amyloid-beta precursor protein | Homo sapiens (human) | Potency | 2.3109 | 1 | 1 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 1.7783 | 1 | 1 |
| AR protein | Homo sapiens (human) | Potency | 21.5975 | 10 | 69 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 38.1307 | 3 | 8 |
| arylsulfatase A | Homo sapiens (human) | Potency | 8.0246 | 1 | 2 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 13.4880 | 4 | 8 |
| Ataxin-2 | Homo sapiens (human) | Potency | 11.1021 | 2 | 8 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 17.5217 | 4 | 9 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 9.8277 | 2 | 9 |
| atrial natriuretic peptide receptor 2 precursor | Homo sapiens (human) | Potency | 16.2746 | 1 | 2 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 6.9923 | 2 | 14 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 70.4948 | 1 | 7 |
| caspase-1 isoform alpha precursor | Homo sapiens (human) | Potency | 4.4965 | 1 | 2 |
| Caspase-7 | Homo sapiens (human) | Potency | 3.9811 | 1 | 2 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 35.4659 | 3 | 16 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 23.1358 | 2 | 4 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 29.2961 | 1 | 12 |
| Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 52.7397 | 2 | 4 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 15.9917 | 2 | 4 |
| Chain A, Breast cancer type 1 susceptibility protein | Homo sapiens (human) | Potency | 27.8298 | 1 | 2 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 39.8107 | 1 | 1 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 23.5700 | 2 | 7 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 29.6254 | 2 | 7 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 44.9448 | 1 | 4 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 22.9197 | 2 | 12 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 15.8114 | 1 | 1 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 32.3678 | 1 | 10 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 29.6254 | 2 | 7 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 51.4541 | 2 | 9 |
| cytochrome P450 2C19 precursor | Homo sapiens (human) | Potency | 6.9937 | 1 | 9 |
| cytochrome P450 2C9 precursor | Homo sapiens (human) | Potency | 16.0474 | 1 | 7 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 13.9994 | 1 | 12 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 23.8074 | 1 | 10 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 20.5218 | 1 | 5 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 13.7100 | 2 | 23 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 12.4551 | 2 | 14 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 23.4465 | 1 | 8 |
| D(1A) dopamine receptor | Homo sapiens (human) | Potency | 9.1796 | 3 | 4 |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Potency | 8.6289 | 1 | 3 |
| DNA dC->dU-editing enzyme APOBEC-3F isoform a | Homo sapiens (human) | Potency | 22.3872 | 1 | 1 |
| DNA polymerase III, partial | Bacillus subtilis | Potency | 29.9349 | 1 | 1 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 45.8933 | 1 | 7 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 25.6278 | 1 | 3 |
| endonuclease IV | Escherichia coli | Potency | 6.5299 | 1 | 4 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 20.4554 | 11 | 93 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 25.8715 | 2 | 9 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 20.7639 | 10 | 68 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 10.6665 | 2 | 23 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 15.5241 | 4 | 24 |
| eyes absent homolog 2 isoform a | Homo sapiens (human) | Potency | 162.7090 | 1 | 2 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 36.3977 | 5 | 13 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 45.7514 | 1 | 2 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 35.7743 | 1 | 4 |
| G | Vesicular stomatitis virus | Potency | 13.9994 | 1 | 12 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 13.6633 | 1 | 12 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 13.6633 | 1 | 12 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 13.6633 | 1 | 12 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 13.6633 | 1 | 12 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 13.6633 | 1 | 12 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 13.6633 | 1 | 12 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 13.6633 | 1 | 12 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 13.6633 | 1 | 12 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 13.6633 | 1 | 12 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 13.6633 | 1 | 12 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 13.6633 | 1 | 12 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 13.6633 | 1 | 12 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 13.6633 | 1 | 12 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 13.6633 | 1 | 12 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 13.6633 | 1 | 12 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 13.6633 | 1 | 12 |
| geminin | Homo sapiens (human) | Potency | 12.2405 | 4 | 22 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 10.7692 | 2 | 22 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 8.2055 | 3 | 9 |
| GLS protein | Homo sapiens (human) | Potency | 17.5536 | 2 | 5 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 20.0394 | 1 | 3 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 21.8396 | 4 | 18 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 24.6847 | 1 | 9 |
| Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 1.9953 | 1 | 1 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 20.4215 | 1 | 2 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 5.0119 | 1 | 1 |
| guanine nucleotide-binding protein G(i) subunit alpha-1 isoform 1 | Homo sapiens (human) | Potency | 10.0000 | 1 | 1 |
| heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) | Homo sapiens (human) | Potency | 24.6912 | 1 | 2 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 41.0759 | 2 | 7 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 16.4411 | 2 | 33 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 24.6058 | 1 | 12 |
| histone deacetylase 9 isoform 3 | Homo sapiens (human) | Potency | 61.1306 | 1 | 1 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 56.6711 | 1 | 3 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 15.0396 | 1 | 3 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 13.9994 | 1 | 12 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 35.4813 | 1 | 1 |
| hypothetical protein, conserved | Trypanosoma brucei | Potency | 33.5314 | 2 | 2 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 16.2423 | 2 | 4 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 13.8964 | 2 | 6 |
| IDH1 | Homo sapiens (human) | Potency | 10.1279 | 1 | 5 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 20.4215 | 1 | 2 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 13.9994 | 1 | 24 |
| Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 23.6756 | 1 | 3 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 28.3708 | 1 | 2 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 28.3708 | 1 | 2 |
| Interferon beta | Homo sapiens (human) | Potency | 13.0279 | 3 | 19 |
| interleukin 8 | Homo sapiens (human) | Potency | 74.9780 | 1 | 1 |
| isocitrate dehydrogenase 1, partial | Homo sapiens (human) | Potency | 44.6684 | 1 | 1 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 9.8766 | 2 | 16 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 19.3561 | 1 | 4 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 24.9449 | 3 | 7 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 11.2202 | 2 | 2 |
| M-phase phosphoprotein 8 | Homo sapiens (human) | Potency | 21.2682 | 1 | 3 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 14.8172 | 2 | 16 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 16.7798 | 2 | 5 |
| muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 10.1506 | 2 | 7 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 1 | 1 |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 11.2202 | 1 | 1 |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 11.2202 | 1 | 1 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 16.9464 | 3 | 6 |
| NFKB1 protein, partial | Homo sapiens (human) | Potency | 10.0442 | 2 | 6 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 30.6785 | 1 | 3 |
| NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 121.2988 | 1 | 4 |
| Nrf2 | Homo sapiens (human) | Potency | 22.3872 | 1 | 1 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 20.7734 | 4 | 19 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 13.2029 | 1 | 4 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 29.4489 | 2 | 7 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 8.4127 | 1 | 1 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 9.8202 | 2 | 12 |
| nuclear receptor subfamily 1, group I, member 2 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1 | 1 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 28.3331 | 3 | 17 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 89.1251 | 1 | 1 |
| Parkin | Homo sapiens (human) | Potency | 17.3582 | 2 | 2 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 38.7603 | 2 | 3 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 16.8417 | 2 | 11 |
| peripheral myelin protein 22 isoform 1 | Homo sapiens (human) | Potency | 48.8868 | 1 | 4 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 19.1056 | 4 | 16 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 18.3888 | 4 | 18 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 11.5320 | 2 | 6 |
| PINK1 | Homo sapiens (human) | Potency | 5.6234 | 1 | 1 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 6.1101 | 1 | 2 |
| polyprotein | Zika virus | Potency | 35.7743 | 1 | 4 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 17.1300 | 1 | 6 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 12.2645 | 1 | 5 |
| PPM1D protein | Homo sapiens (human) | Potency | 8.3108 | 1 | 4 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 20.4367 | 3 | 16 |
| pregnane X receptor | Rattus norvegicus (Norway rat) | Potency | 49.8442 | 1 | 3 |
| progesterone receptor | Homo sapiens (human) | Potency | 23.8332 | 2 | 10 |
| Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 93.1443 | 2 | 3 |
| Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 79.6659 | 2 | 4 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 19.7480 | 2 | 14 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 38.2686 | 1 | 5 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 17.0029 | 1 | 11 |
| relaxin receptor 1 isoform 1 | Homo sapiens (human) | Potency | 0.0388 | 1 | 1 |
| relaxin receptor 2 isoform 1 | Homo sapiens (human) | Potency | 0.0488 | 1 | 1 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 29.2512 | 3 | 20 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 14.8101 | 4 | 20 |
| RGS12 | Homo sapiens (human) | Potency | 10.0000 | 1 | 1 |
| serine-protein kinase ATM isoform a | Homo sapiens (human) | Potency | 31.6228 | 1 | 1 |
| serine/threonine-protein kinase mTOR isoform 1 | Homo sapiens (human) | Potency | 0.5212 | 1 | 1 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 16.2781 | 1 | 4 |
| Single-stranded DNA cytosine deaminase | Homo sapiens (human) | Potency | 79.4328 | 1 | 3 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 18.4621 | 3 | 9 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 18.4621 | 3 | 9 |
| Smad3 | Homo sapiens (human) | Potency | 8.5956 | 3 | 5 |
| snurportin-1 | Homo sapiens (human) | Potency | 20.4215 | 1 | 2 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 27.2092 | 1 | 11 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 16.0193 | 1 | 11 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 28.9342 | 1 | 2 |
| TDP1 protein | Homo sapiens (human) | Potency | 16.5127 | 2 | 50 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 67.4465 | 1 | 3 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 19.0794 | 4 | 25 |
| Thrombopoietin | Homo sapiens (human) | Potency | 9.9433 | 2 | 6 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 15.2591 | 3 | 23 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 22.1751 | 3 | 5 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 20.4841 | 7 | 35 |
| thyrotropin-releasing hormone receptor | Homo sapiens (human) | Potency | 11.9877 | 1 | 1 |
| transcriptional regulator ERG isoform 3 | Homo sapiens (human) | Potency | 28.1838 | 1 | 1 |
| tumor susceptibility gene 101 protein | Homo sapiens (human) | Potency | 35.3981 | 3 | 3 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 10.3592 | 3 | 5 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 6.1101 | 1 | 2 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 6.1101 | 1 | 2 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 37.7409 | 2 | 8 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 23.1687 | 2 | 8 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 23.7510 | 3 | 11 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 32.2733 | 1 | 10 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 24.6847 | 1 | 9 |
| Vpr | Human immunodeficiency virus 1 | Potency | 22.1060 | 1 | 2 |
| WRN | Homo sapiens (human) | Potency | 31.6228 | 1 | 1 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 2-5A-dependent ribonuclease | Homo sapiens (human) | IC50 | 190.0000 | 1 | 1 |
| 3-oxo-5-alpha-steroid 4-dehydrogenase 1 | Rattus norvegicus (Norway rat) | IC50 | 12.2000 | 1 | 1 |
| 3-oxo-5-alpha-steroid 4-dehydrogenase 2 | Rattus norvegicus (Norway rat) | IC50 | 12.2000 | 1 | 1 |
| 3',5'-cyclic-AMP phosphodiesterase | Sus scrofa (pig) | IC50 | 8.2233 | 3 | 3 |
| 4-aminobutyrate aminotransferase, mitochondrial | Rattus norvegicus (Norway rat) | IC50 | 2.4000 | 1 | 2 |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | IC50 | 0.0410 | 1 | 1 |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | Ki | 0.1710 | 1 | 1 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | Ki | 0.9660 | 2 | 2 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | IC50 | 1.3120 | 1 | 1 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | Ki | 0.3246 | 3 | 3 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | Ki | 0.4146 | 2 | 2 |
| 5-hydroxytryptamine receptor 7 | Homo sapiens (human) | Ki | 0.0430 | 1 | 1 |
| 90-kda heat shock protein beta HSP90 beta, partial | Homo sapiens (human) | IC50 | 21.0682 | 1 | 1 |
| Acetylcholinesterase | Homo sapiens (human) | IC50 | 1.0000 | 2 | 2 |
| Acetylcholinesterase | Homo sapiens (human) | Ki | 1.0000 | 1 | 2 |
| Acetylcholinesterase | Bos taurus (cattle) | IC50 | 0.5000 | 1 | 1 |
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | IC50 | 5,000.0000 | 1 | 1 |
| Adenosine receptor A2a | Rattus norvegicus (Norway rat) | IC50 | 5,000.0000 | 1 | 1 |
| Adenosine receptor A3 | Homo sapiens (human) | IC50 | 5.2080 | 1 | 1 |
| Adenosine receptor A3 | Homo sapiens (human) | Ki | 2.9430 | 1 | 1 |
| Adenylate cyclase type 1 | Homo sapiens (human) | IC50 | 0.0955 | 2 | 2 |
| Aldo-keto reductase family 1 member B1 | Homo sapiens (human) | IC50 | 566.6600 | 1 | 1 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 5.2080 | 1 | 1 |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | Ki | 0.0501 | 3 | 3 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 1.4966 | 2 | 2 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 5.2080 | 1 | 1 |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | Ki | 0.0501 | 3 | 3 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 2.9430 | 1 | 1 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | IC50 | 0.3820 | 1 | 1 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | Ki | 0.1430 | 1 | 1 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | IC50 | 0.3040 | 1 | 1 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | Ki | 0.1390 | 1 | 1 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | IC50 | 1.1750 | 1 | 1 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | Ki | 0.1710 | 1 | 1 |
| Amine oxidase [flavin-containing] A | Homo sapiens (human) | IC50 | 38.8000 | 1 | 1 |
| Amine oxidase [flavin-containing] A | Homo sapiens (human) | Ki | 10.5000 | 1 | 1 |
| Amine oxidase [flavin-containing] A | Rattus norvegicus (Norway rat) | Ki | 4.8000 | 1 | 1 |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | IC50 | 34.7133 | 3 | 3 |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | Ki | 9.5000 | 1 | 1 |
| Amine oxidase [flavin-containing] B | Rattus norvegicus (Norway rat) | Ki | 10.9000 | 1 | 1 |
| Amyloid-beta precursor protein | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | IC50 | 103.2714 | 1 | 7 |
| ATP-binding cassette sub-family C member 8 | Homo sapiens (human) | IC50 | 1.2850 | 1 | 1 |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | IC50 | 56.4429 | 5 | 7 |
| ATP-sensitive inward rectifier potassium channel 11 | Homo sapiens (human) | IC50 | 1.2850 | 1 | 1 |
| Aurora kinase A | Homo sapiens (human) | Ki | 100.0000 | 1 | 1 |
| Aurora kinase B | Homo sapiens (human) | Ki | 100.0000 | 1 | 1 |
| Beta-secretase 1 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Bile salt export pump | Homo sapiens (human) | IC50 | 161.8763 | 7 | 19 |
| Bile salt export pump | Rattus norvegicus (Norway rat) | IC50 | 21.1667 | 2 | 3 |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | IC50 | 4.7500 | 2 | 2 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A | Homo sapiens (human) | IC50 | 329.3000 | 10 | 10 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B | Homo sapiens (human) | IC50 | 329.3000 | 10 | 10 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C | Homo sapiens (human) | IC50 | 329.3000 | 10 | 10 |
| cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A | Homo sapiens (human) | Ki | 1.0000 | 1 | 1 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) | IC50 | 3.2500 | 2 | 2 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Homo sapiens (human) | IC50 | 3.2500 | 2 | 2 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Homo sapiens (human) | IC50 | 3.2500 | 2 | 2 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Homo sapiens (human) | IC50 | 16.3857 | 3 | 7 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 7B | Homo sapiens (human) | Ki | 0.6000 | 1 | 1 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 | 133.0000 | 1 | 6 |
| Cannabinoid receptor 1 | Rattus norvegicus (Norway rat) | IC50 | 50.0000 | 1 | 1 |
| Carbonic anhydrase 1 | Homo sapiens (human) | IC50 | 2,710.0000 | 1 | 1 |
| Carbonic anhydrase 1 | Homo sapiens (human) | Ki | 7,530.0000 | 1 | 1 |
| Carbonic anhydrase 2 | Homo sapiens (human) | IC50 | 580.4850 | 2 | 2 |
| Carbonic anhydrase 2 | Homo sapiens (human) | Ki | 3,660.0000 | 1 | 1 |
| Caspase-3 | Homo sapiens (human) | IC50 | 46.7400 | 2 | 2 |
| Caspase-7 | Homo sapiens (human) | IC50 | 137.4000 | 1 | 1 |
| cGMP-dependent 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | IC50 | 91.0024 | 13 | 17 |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | IC50 | 5.2156 | 36 | 43 |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | Ki | 0.1500 | 1 | 1 |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) | IC50 | 2.9605 | 31 | 34 |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) | Ki | 0.1500 | 1 | 1 |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Bos taurus (cattle) | IC50 | 5.0000 | 1 | 1 |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | IC50 | 29.5638 | 8 | 12 |
| Class A sortase SrtA | Staphylococcus aureus | IC50 | 129.0000 | 1 | 1 |
| Coagulation factor X | Homo sapiens (human) | IC50 | 0.0034 | 2 | 2 |
| Coagulation factor X | Homo sapiens (human) | Ki | 0.0006 | 1 | 1 |
| Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha' | Homo sapiens (human) | Ki | 0.1250 | 1 | 1 |
| CREB-binding protein | Homo sapiens (human) | IC50 | 1.3000 | 1 | 1 |
| Cruzipain | Trypanosoma cruzi | IC50 | 211.5000 | 2 | 2 |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | IC50 | 500.0000 | 1 | 1 |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | IC50 | 500.0000 | 1 | 1 |
| Cyclin-dependent kinase 3 | Homo sapiens (human) | IC50 | 500.0000 | 1 | 1 |
| Cytochrome P450 2B6 | Homo sapiens (human) | IC50 | 0.4050 | 2 | 2 |
| Cytochrome P450 2B6 | Homo sapiens (human) | Ki | 0.9000 | 2 | 3 |
| Cytochrome P450 2C19 | Homo sapiens (human) | IC50 | 0.6678 | 1 | 1 |
| Cytochrome P450 2C19 | Homo sapiens (human) | Ki | 34.8667 | 2 | 3 |
| Cytochrome P450 2C8 | Homo sapiens (human) | Ki | 26.3500 | 3 | 4 |
| Cytochrome P450 2C9 | Homo sapiens (human) | IC50 | 11.9333 | 2 | 3 |
| Cytochrome P450 2D6 | Homo sapiens (human) | IC50 | 11.5309 | 3 | 3 |
| Cytochrome P450 2D6 | Homo sapiens (human) | Ki | 0.0501 | 1 | 1 |
| Cytochrome P450 2J2 | Homo sapiens (human) | IC50 | 21.8000 | 1 | 1 |
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 | 27.3000 | 1 | 1 |
| Cytochrome P450 3A4 | Homo sapiens (human) | Ki | 0.0200 | 1 | 1 |
| Cytoplasmic tyrosine-protein kinase BMX | Homo sapiens (human) | IC50 | 281.0000 | 1 | 1 |
| D | Rattus norvegicus (Norway rat) | Ki | 2.9000 | 1 | 1 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | Ki | 2.8000 | 1 | 1 |
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Homo sapiens (human) | IC50 | 6.5650 | 2 | 2 |
| DNA (cytosine-5)-methyltransferase 1 | Homo sapiens (human) | IC50 | 500.0000 | 1 | 1 |
| DNA (cytosine-5)-methyltransferase 3-like | Homo sapiens (human) | IC50 | 300.0000 | 1 | 1 |
| DNA (cytosine-5)-methyltransferase 3A | Homo sapiens (human) | IC50 | 300.0000 | 1 | 1 |
| Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A | Homo sapiens (human) | Ki | 0.4000 | 1 | 1 |
| Dual specificity protein kinase TTK | Homo sapiens (human) | Ki | 100.0000 | 1 | 1 |
| Endothelial PAS domain-containing protein 1 | Homo sapiens (human) | IC50 | 19.5500 | 4 | 4 |
| Epidermal growth factor receptor | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Equilibrative nucleoside transporter 1 | Homo sapiens (human) | IC50 | 0.0298 | 4 | 6 |
| Equilibrative nucleoside transporter 1 | Homo sapiens (human) | Ki | 0.0084 | 3 | 3 |
| Equilibrative nucleoside transporter 2 | Rattus norvegicus (Norway rat) | IC50 | 8.8000 | 1 | 1 |
| Estrogen receptor | Homo sapiens (human) | IC50 | 0.0625 | 1 | 2 |
| Estrogen receptor beta | Homo sapiens (human) | IC50 | 0.0625 | 1 | 2 |
| Exopolyphosphatase PRUNE1 | Homo sapiens (human) | IC50 | 0.7800 | 1 | 1 |
| Fatty acid synthase | Gallus gallus (chicken) | IC50 | 8.3700 | 2 | 2 |
| Fatty acid-binding protein, liver | Rattus norvegicus (Norway rat) | Ki | 2,064.0000 | 2 | 2 |
| Forkhead box protein M1 | Homo sapiens (human) | IC50 | 122.4000 | 1 | 1 |
| Forkhead box protein M1 | Homo sapiens (human) | Ki | 0.0520 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | IC50 | 0.3500 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | IC50 | 66.8933 | 3 | 3 |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | IC50 | 100.0000 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | IC50 | 0.6800 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | IC50 | 100.0000 | 1 | 1 |
| Glutathione hydrolase 1 proenzyme | Homo sapiens (human) | IC50 | 36.0000 | 1 | 1 |
| Glutathione reductase, mitochondrial | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| heat shock protein HSP 90-alpha isoform 2 | Homo sapiens (human) | IC50 | 21.0682 | 1 | 1 |
| Hepatocyte growth factor receptor | Homo sapiens (human) | IC50 | 215.0000 | 1 | 1 |
| High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A | Homo sapiens (human) | Ki | 0.6000 | 1 | 1 |
| High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A | Homo sapiens (human) | IC50 | 21.6400 | 1 | 5 |
| Histamine H1 receptor | Homo sapiens (human) | Ki | 0.0012 | 3 | 3 |
| Histamine H3 receptor | Homo sapiens (human) | Ki | 0.1514 | 3 | 3 |
| Histone acetyltransferase p300 | Homo sapiens (human) | IC50 | 1.3000 | 1 | 1 |
| Histone deacetylase | Plasmodium falciparum (malaria parasite P. falciparum) | IC50 | 10.0000 | 1 | 1 |
| Histone deacetylase 1 | Homo sapiens (human) | IC50 | 75.0000 | 1 | 1 |
| Histone deacetylase 11 | Homo sapiens (human) | IC50 | 75.0000 | 1 | 1 |
| Histone deacetylase 2 | Homo sapiens (human) | IC50 | 75.0000 | 1 | 1 |
| Histone deacetylase 3 | Homo sapiens (human) | IC50 | 75.0000 | 2 | 2 |
| Histone deacetylase 3 | Homo sapiens (human) | Ki | 75.0000 | 1 | 1 |
| Histone deacetylase 4 | Homo sapiens (human) | IC50 | 75.0000 | 1 | 1 |
| Histone deacetylase 5 | Homo sapiens (human) | IC50 | 75.0000 | 1 | 1 |
| Histone deacetylase 6 | Homo sapiens (human) | IC50 | 75.0000 | 2 | 2 |
| Histone deacetylase 6 | Homo sapiens (human) | Ki | 75.0000 | 1 | 1 |
| Histone deacetylase 7 | Homo sapiens (human) | IC50 | 75.0000 | 1 | 1 |
| Histone deacetylase 8 | Homo sapiens (human) | IC50 | 75.0000 | 1 | 1 |
| Histone deacetylase 9 | Homo sapiens (human) | IC50 | 75.0000 | 1 | 1 |
| Hypoxia-inducible factor 1-alpha | Homo sapiens (human) | IC50 | 12.5827 | 11 | 11 |
| Indoleamine 2,3-dioxygenase 1 | Mus musculus (house mouse) | IC50 | 61.0000 | 1 | 1 |
| Indoleamine 2,3-dioxygenase 2 | Mus musculus (house mouse) | IC50 | 4.5000 | 1 | 1 |
| Inhibitor of nuclear factor kappa-B kinase subunit alpha | Homo sapiens (human) | IC50 | 500.0000 | 1 | 1 |
| Inhibitor of nuclear factor kappa-B kinase subunit beta | Homo sapiens (human) | IC50 | 500.0000 | 1 | 1 |
| Inner centromere protein | Homo sapiens (human) | Ki | 100.0000 | 1 | 1 |
| Insulin-like growth factor 1 receptor | Homo sapiens (human) | IC50 | 500.0000 | 1 | 1 |
| Integrin alpha-IIb | Homo sapiens (human) | IC50 | 15.1614 | 4 | 7 |
| Integrin beta-3 | Homo sapiens (human) | IC50 | 15.1614 | 4 | 7 |
| large T antigen | Betapolyomavirus macacae | IC50 | 19.2500 | 1 | 2 |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | IC50 | 500.0000 | 1 | 1 |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | IC50 | 250.6190 | 2 | 2 |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | IC50 | 500.0000 | 1 | 1 |
| Monoglyceride lipase | Rattus norvegicus (Norway rat) | IC50 | 0.3065 | 1 | 1 |
| MPI protein | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | IC50 | 26.0000 | 1 | 1 |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | IC50 | 74.0000 | 1 | 1 |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | IC50 | 56.5778 | 2 | 9 |
| Multidrug resistance-associated protein 5 | Homo sapiens (human) | IC50 | 40.0000 | 1 | 2 |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | IC50 | 6.3096 | 1 | 1 |
| Myeloperoxidase | Homo sapiens (human) | IC50 | 200.0000 | 1 | 1 |
| N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 | Homo sapiens (human) | IC50 | 13.2000 | 1 | 1 |
| NACHT, LRR and PYD domains-containing protein 3 | Mus musculus (house mouse) | IC50 | 12.0000 | 1 | 1 |
| NAD-dependent histone deacetylase SIR2 | Saccharomyces cerevisiae S288C | IC50 | 67.0000 | 2 | 2 |
| NAD-dependent protein deacetylase HST2 | Saccharomyces cerevisiae S288C | IC50 | 650.0000 | 1 | 2 |
| NAD-dependent protein deacetylase sirtuin-1 | Homo sapiens (human) | IC50 | 449.0500 | 3 | 4 |
| NAD-dependent protein deacetylase sirtuin-2 | Homo sapiens (human) | IC50 | 112.9000 | 1 | 1 |
| NAD-dependent protein deacylase sirtuin-5, mitochondrial | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Neuraminidase | Influenza A virus (A/Wilson-Smith/1933(H1N1)) | IC50 | 47.0667 | 3 | 3 |
| neutrophil cytosol factor 1 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| NF-kappa-B essential modulator | Homo sapiens (human) | IC50 | 500.0000 | 1 | 1 |
| Nicotinate phosphoribosyltransferase | Homo sapiens (human) | Ki | 0.0005 | 1 | 1 |
| Nuclear factor NF-kappa-B p100 subunit | Homo sapiens (human) | IC50 | 2.0000 | 1 | 1 |
| Nuclear factor NF-kappa-B p105 subunit | Homo sapiens (human) | IC50 | 2.0000 | 1 | 1 |
| Nuclear receptor corepressor 2 | Homo sapiens (human) | IC50 | 75.0000 | 1 | 1 |
| Nuclear receptor corepressor 2 | Homo sapiens (human) | Ki | 75.0000 | 1 | 1 |
| nuclear receptor subfamily 0 group B member 1 | Homo sapiens (human) | IC50 | 1.7290 | 1 | 1 |
| Ornithine decarboxylase | Rattus norvegicus (Norway rat) | IC50 | 0.0004 | 1 | 1 |
| P2Y purinoceptor 12 | Homo sapiens (human) | IC50 | 0.7214 | 9 | 11 |
| P2Y purinoceptor 12 | Homo sapiens (human) | Ki | 0.0080 | 2 | 2 |
| P2Y purinoceptor 13 | Homo sapiens (human) | IC50 | 1.3980 | 1 | 1 |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | IC50 | 1.0300 | 6 | 6 |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | Ki | 0.3168 | 5 | 5 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | Homo sapiens (human) | IC50 | 500.0000 | 1 | 1 |
| Phosphodiesterase | Bos taurus (cattle) | IC50 | 1.0000 | 1 | 1 |
| Phosphodiesterase | Sus scrofa (pig) | IC50 | 48.2810 | 3 | 3 |
| phosphomannomutase 2 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Platelet-activating factor receptor | Cavia porcellus (domestic guinea pig) | IC50 | 4.5000 | 1 | 1 |
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | IC50 | 500.0000 | 1 | 1 |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | IC50 | 500.0000 | 1 | 1 |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | IC50 | 75.0000 | 1 | 1 |
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | IC50 | 40.0000 | 3 | 3 |
| Polyunsaturated fatty acid lipoxygenase ALOX12 | Homo sapiens (human) | IC50 | 0.3500 | 2 | 2 |
| Polyunsaturated fatty acid lipoxygenase ALOX12 | Mus musculus (house mouse) | IC50 | 1.0000 | 1 | 1 |
| Polyunsaturated fatty acid lipoxygenase ALOX12 | Homo sapiens (human) | Ki | 0.5350 | 2 | 2 |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Homo sapiens (human) | IC50 | 9.7000 | 1 | 1 |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | IC50 | 6.9560 | 1 | 1 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | IC50 | 46.0793 | 6 | 6 |
| Prostacyclin receptor | Homo sapiens (human) | IC50 | 0.0522 | 6 | 8 |
| Prostacyclin receptor | Homo sapiens (human) | Ki | 1.1643 | 8 | 9 |
| Prostacyclin receptor | Rattus norvegicus (Norway rat) | Ki | 0.0010 | 1 | 1 |
| Prostaglandin E2 receptor EP1 subtype | Mus musculus (house mouse) | Ki | 0.0375 | 3 | 4 |
| Prostaglandin E2 receptor EP2 subtype | Mus musculus (house mouse) | Ki | 0.0478 | 3 | 4 |
| Prostaglandin E2 receptor EP3 subtype | Homo sapiens (human) | Ki | 3.7000 | 1 | 1 |
| Prostaglandin E2 receptor EP3 subtype | Mus musculus (house mouse) | Ki | 0.0050 | 3 | 3 |
| Prostaglandin E2 receptor EP4 subtype | Mus musculus (house mouse) | Ki | 0.0032 | 3 | 4 |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | IC50 | 306.9229 | 11 | 11 |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | IC50 | 1,813.8445 | 37 | 40 |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | Ki | 62.0000 | 1 | 1 |
| Prostaglandin G/H synthase 1 | Bos taurus (cattle) | IC50 | 2,018.7250 | 5 | 6 |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | IC50 | 907.5235 | 24 | 26 |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | IC50 | 523.7468 | 22 | 22 |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | Ki | 52.0000 | 1 | 1 |
| Prostaglandin G/H synthase 2 | Bos taurus (cattle) | IC50 | 1,500.0000 | 1 | 2 |
| Prostaglandin-H2 D-isomerase | Mus musculus (house mouse) | IC50 | 1,500.0000 | 1 | 1 |
| Protein tyrosine phosphatase type IVA 3 | Homo sapiens (human) | IC50 | 46.2000 | 1 | 1 |
| Protein-tyrosine kinase 6 | Homo sapiens (human) | IC50 | 267.0000 | 1 | 1 |
| Proteinase-activated receptor 1 | Homo sapiens (human) | IC50 | 0.0626 | 8 | 8 |
| Proteinase-activated receptor 1 | Homo sapiens (human) | Ki | 0.0077 | 5 | 5 |
| Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | IC50 | 38.4000 | 1 | 1 |
| Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | Ki | 7.0000 | 1 | 2 |
| Replicase polyprotein 1ab | Betacoronavirus England 1 | IC50 | 10.0000 | 1 | 1 |
| Replicase polyprotein 1ab | Human coronavirus 229E | IC50 | 38.4000 | 1 | 1 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | IC50 | 13.2933 | 2 | 3 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | IC50 | 28.9650 | 3 | 4 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | Ki | 35.6000 | 1 | 1 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | Ki | 35.6000 | 2 | 2 |
| Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma | Homo sapiens (human) | Ki | 0.1250 | 1 | 1 |
| Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta | Homo sapiens (human) | Ki | 0.1250 | 1 | 1 |
| Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gamma | Homo sapiens (human) | Ki | 0.1250 | 1 | 1 |
| Rho-associated protein kinase 2 | Rattus norvegicus (Norway rat) | IC50 | 100.0000 | 1 | 2 |
| Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha | Homo sapiens (human) | Ki | 0.1250 | 1 | 1 |
| Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta | Homo sapiens (human) | Ki | 0.1250 | 1 | 1 |
| Seed linoleate 13S-lipoxygenase-1 | Glycine max (soybean) | IC50 | 1.3750 | 1 | 2 |
| Serine/threonine-protein kinase Chk1 | Homo sapiens (human) | IC50 | 500.0000 | 1 | 1 |
| Serine/threonine-protein kinase PLK1 | Xenopus laevis (African clawed frog) | IC50 | 21.4000 | 2 | 2 |
| Serine/threonine-protein kinase PLK3 | Homo sapiens (human) | IC50 | 97.0250 | 8 | 8 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | IC50 | 0.4260 | 1 | 1 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | Ki | 0.1790 | 1 | 1 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | IC50 | 0.5620 | 1 | 1 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | Ki | 0.2990 | 1 | 1 |
| Solute carrier family 2, facilitated glucose transporter member 1 | Homo sapiens (human) | IC50 | 4.1000 | 1 | 1 |
| Solute carrier family 2, facilitated glucose transporter member 3 | Homo sapiens (human) | IC50 | 3.9000 | 1 | 1 |
| Solute carrier family 2, facilitated glucose transporter member 4 | Homo sapiens (human) | IC50 | 3.9000 | 1 | 1 |
| Solute carrier family 22 member 1 | Mus musculus (house mouse) | IC50 | 3.9000 | 1 | 1 |
| Solute carrier family 22 member 1 | Rattus norvegicus (Norway rat) | IC50 | 8.9000 | 3 | 3 |
| Solute carrier family 22 member 1 | Rattus norvegicus (Norway rat) | Ki | 30.0000 | 2 | 2 |
| Solute carrier family 22 member 1 | Homo sapiens (human) | IC50 | 81.0000 | 1 | 1 |
| Solute carrier family 22 member 1 | Homo sapiens (human) | Ki | 73.9000 | 1 | 1 |
| Solute carrier family 22 member 2 | Homo sapiens (human) | IC50 | 2.6000 | 1 | 1 |
| Solute carrier family 22 member 2 | Mus musculus (house mouse) | IC50 | 312.0000 | 1 | 1 |
| Solute carrier family 22 member 2 | Rattus norvegicus (Norway rat) | IC50 | 229.2500 | 4 | 4 |
| Solute carrier family 22 member 2 | Homo sapiens (human) | Ki | 50.0000 | 1 | 1 |
| Solute carrier family 22 member 2 | Rattus norvegicus (Norway rat) | Ki | 36.0000 | 1 | 1 |
| Solute carrier family 22 member 20 | Mus musculus (house mouse) | Ki | 101.6645 | 1 | 2 |
| Solute carrier family 22 member 3 | Homo sapiens (human) | Ki | 738.0000 | 1 | 1 |
| Solute carrier family 22 member 4 | Rattus norvegicus (Norway rat) | IC50 | 1,000.0000 | 1 | 1 |
| Solute carrier family 22 member 6 | Mus musculus (house mouse) | Ki | 689.4155 | 1 | 2 |
| Solute carrier family 22 member 6 | Rattus norvegicus (Norway rat) | Ki | 428.0000 | 1 | 1 |
| Solute carrier organic anion transporter family member 2B1 | Rattus norvegicus (Norway rat) | IC50 | 0.0358 | 1 | 1 |
| steroidogenic factor 1 | Homo sapiens (human) | IC50 | 67.5470 | 1 | 1 |
| Sterol O-acyltransferase 1 | Homo sapiens (human) | IC50 | 1.0000 | 1 | 1 |
| Sterol O-acyltransferase 1 | Rattus norvegicus (Norway rat) | IC50 | 1.0000 | 1 | 1 |
| Substance-K receptor | Cavia porcellus (domestic guinea pig) | IC50 | 46.5000 | 1 | 1 |
| Substance-P receptor | Cavia porcellus (domestic guinea pig) | IC50 | 24.4500 | 2 | 2 |
| Thioredoxin glutathione reductase | Schistosoma mansoni | IC50 | 5.6500 | 2 | 2 |
| Thioredoxin reductase 1, cytoplasmic | Homo sapiens (human) | IC50 | 200.0000 | 3 | 3 |
| Thioredoxin reductase 1, cytoplasmic | Rattus norvegicus (Norway rat) | IC50 | 400.0000 | 1 | 1 |
| Thioredoxin reductase 2, mitochondrial | Homo sapiens (human) | IC50 | 200.0000 | 3 | 3 |
| Thioredoxin reductase 3 | Homo sapiens (human) | IC50 | 200.0000 | 3 | 3 |
| Thromboxane-A synthase | Homo sapiens (human) | IC50 | 2.9660 | 1 | 1 |
| Thromboxane-A synthase | Homo sapiens (human) | Ki | 0.1000 | 1 | 1 |
| Transcription factor p65 | Homo sapiens (human) | IC50 | 2.5000 | 2 | 2 |
| Triosephosphate isomerase | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
| Triosephosphate isomerase, glycosomal | Trypanosoma cruzi | IC50 | 6.5000 | 1 | 1 |
| Tyrosinase | Mus musculus (house mouse) | Ki | 2,800.0000 | 3 | 3 |
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | IC50 | 500.0000 | 1 | 1 |
| Tyrosine-protein kinase BTK | Homo sapiens (human) | IC50 | 6.1750 | 4 | 4 |
| Tyrosine-protein kinase BTK | Mus musculus (house mouse) | IC50 | 2.5000 | 1 | 1 |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | IC50 | 240.0000 | 1 | 1 |
| Tyrosine-protein kinase JAK2 | Homo sapiens (human) | IC50 | 500.0000 | 1 | 1 |
| Tyrosine-protein kinase Yes | Homo sapiens (human) | IC50 | 500.0000 | 1 | 1 |
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | IC50 | 44.1000 | 3 | 3 |
| UDP-glucuronosyltransferase 1-6 | Homo sapiens (human) | Ki | 20.0000 | 1 | 1 |
| Urotensin-2 receptor | Rattus norvegicus (Norway rat) | IC50 | 0.3000 | 1 | 2 |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | IC50 | 240.3500 | 2 | 2 |
| Voltage-dependent L-type calcium channel subunit alpha-1D | Homo sapiens (human) | IC50 | 240.3500 | 2 | 2 |
| Voltage-dependent L-type calcium channel subunit alpha-1F | Homo sapiens (human) | IC50 | 240.3500 | 2 | 2 |
| Voltage-dependent L-type calcium channel subunit alpha-1S | Homo sapiens (human) | IC50 | 240.3500 | 2 | 2 |
| Voltage-dependent T-type calcium channel subunit alpha-1G | Homo sapiens (human) | IC50 | 1.0000 | 1 | 1 |
| Voltage-dependent T-type calcium channel subunit alpha-1H | Homo sapiens (human) | IC50 | 1.0000 | 1 | 1 |